AGIO
Income statement / Annual
Last year (2024), Agios Pharmaceuticals, Inc.'s total revenue was $36.50 M,
an increase of 36.07% from the previous year.
In 2024, Agios Pharmaceuticals, Inc.'s net income was $673.73 M.
See Agios Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$36.50 M |
$26.82 M |
$14.24 M |
$0.00 |
$0.00 |
$117.91 M |
$94.39 M |
$43.01 M |
$69.89 M |
$59.12 M |
| Cost of Revenue |
$4.17 M
|
$9.50 M
|
$1.70 M
|
$18.78 M
|
$18.77 M
|
$1.32 M
|
$1.40 M
|
$292.68 M
|
$220.16 M
|
$141.83 M
|
| Gross Profit |
$32.33 M
|
$17.32 M
|
$12.54 M
|
-$18.78 M
|
-$18.77 M
|
$116.60 M
|
$92.99 M
|
-$249.67 M
|
-$150.27 M
|
-$82.71 M
|
| Gross Profit Ratio |
0.89
|
0.65
|
0.88
|
0
|
0
|
0.99
|
0.99
|
-5.8
|
-2.15
|
-1.4
|
| Research and Development Expenses |
$301.29 M
|
$288.90 M
|
$279.91 M
|
$256.97 M
|
$211.02 M
|
$410.89 M
|
$341.32 M
|
$292.68 M
|
$220.16 M
|
$141.83 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$71.12 M
|
$50.71 M
|
$35.99 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$156.78 M
|
$119.90 M
|
$121.67 M
|
$121.45 M
|
$106.12 M
|
$132.03 M
|
$114.15 M
|
$71.12 M
|
$50.71 M
|
$35.99 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$18.78 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$458.07 M
|
$408.81 M
|
$401.58 M
|
$359.64 M
|
$317.14 M
|
$542.93 M
|
$455.47 M
|
$363.81 M
|
$270.88 M
|
$177.82 M
|
| Cost And Expenses |
$462.24 M
|
$418.31 M
|
$403.29 M
|
$378.42 M
|
$335.92 M
|
$544.25 M
|
$456.87 M
|
$363.81 M
|
$270.88 M
|
$177.82 M
|
| Interest Income |
$48.08 M
|
$33.34 M
|
$12.79 M
|
$836.00 K
|
$6.61 M
|
$14.86 M
|
$16.45 M
|
$6.12 M
|
$2.51 M
|
$968.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$17.83 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$5.65 M
|
$6.62 M
|
$8.56 M
|
$18.78 M
|
$18.77 M
|
$16.62 M
|
$7.17 M
|
$6.43 M
|
$5.71 M
|
$3.34 M
|
| EBITDA |
-$420.08 M |
-$384.86 M |
-$380.48 M |
-$337.73 M |
-$310.53 M |
-$394.85 M |
-$338.86 M |
-$314.36 M |
-$195.28 M |
-$115.36 M |
| EBITDA Ratio |
-11.51
|
-14.35
|
-26.72
|
0
|
0
|
-3.35
|
-3.59
|
-7.31
|
-2.79
|
-1.95
|
| Operating Income Ratio |
-11.66
|
-14.6
|
-27.32
|
0
|
0
|
-3.62
|
-3.84
|
-7.46
|
-2.88
|
-2.01
|
| Total Other Income/Expenses Net |
$1.14 B
|
$39.40 M
|
$157.25 M
|
$21.91 M
|
$6.61 M
|
$14.86 M
|
$16.45 M
|
$6.12 M
|
$2.51 M
|
$968.00 K
|
| Income Before Tax |
$717.97 M
|
-$352.09 M
|
-$231.80 M
|
-$356.51 M
|
-$329.31 M
|
-$411.47 M
|
-$346.03 M
|
-$314.67 M
|
-$198.47 M
|
-$117.73 M
|
| Income Before Tax Ratio |
19.67
|
-13.13
|
-16.28
|
0
|
0
|
-3.49
|
-3.67
|
-7.32
|
-2.84
|
-1.99
|
| Income Tax Expense |
$44.24 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$426.00 K
|
| Net Income |
$673.73 M
|
-$352.09 M
|
-$231.80 M
|
$1.60 B
|
-$327.37 M
|
-$411.47 M
|
-$346.03 M
|
-$314.67 M
|
-$198.47 M
|
-$117.73 M
|
| Net Income Ratio |
18.46
|
-13.13
|
-16.28
|
0
|
0
|
-3.49
|
-3.67
|
-7.32
|
-2.84
|
-1.99
|
| EPS |
11.86 |
-6.33 |
-4.23 |
-6.36 |
-4.74 |
-6.61 |
-6.03 |
-6.75 |
-5.07 |
-3.15 |
| EPS Diluted |
11.64 |
-6.33 |
-4.23 |
-6.36 |
-4.74 |
-6.61 |
-6.03 |
-6.75 |
-5.07 |
-3.15 |
| Weighted Average Shares Out |
$56.81 M
|
$55.65 M
|
$54.79 M
|
$60.45 M
|
$69.00 M
|
$59.99 M
|
$57.42 M
|
$46.59 M
|
$39.13 M
|
$37.43 M
|
| Weighted Average Shares Out Diluted |
$57.89 M
|
$55.65 M
|
$54.79 M
|
$60.45 M
|
$69.00 M
|
$59.99 M
|
$57.42 M
|
$46.59 M
|
$39.13 M
|
$37.43 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
